08:00 AM EDT, 06/05/2025 (MT Newswires) -- Clearmind Medicine ( CMND ) said it has enrolled the first patient for its phase 1/2a clinical trial of CMND-100, an oral drug candidate aimed at treating alcohol use disorder.

The trial is aimed at assessing the safety, tolerability, and pharmacokinetic effects of CMND-100 in potentially reducing alcohol cravings and consumption, the clinical-stage company said.

Shares of the company were up 6% in recent premarket activity.